Izraēla - ivrits - Ministry of Health

דיאסורין בע"מ - אחר - בתחומי אימונולוגיה ומיקרוביולוגיה in vitro ביצוע בדיקות אבחוניות

Izraēla - ivrits - Ministry of Health

דיאסורין בע"מ - אחר - בתחומי אימונולוגינה ומיקרוביולוגיה in vitro ביצוע בדיקות אבחוניות

Izraēla - ivrits - Ministry of Health

גלקסוסמיתקליין (ישראל) בע"מ - כלל האוכלוסיה - מדבקות לשימוש ביתי לסיוע בטיפול בפצעי קור. מסייעות במניעת הצטלקות, בעלות שכבה דקה היוצרת סביבה נקייה מחיידקים ובכך מסייעת בקידום ההחלמה. מבודדת את האזור הנגוע להקטנת הסיכון לזיהום והתפשטות.

Izraēla - ivrits - Ministry of Health

avi villinger - כלל האוכלוסיה - קונדום מלטקס טבעי המכיל חומר סיכה

Izraēla - ivrits - Ministry of Health

ס. י. ר. א. מ. בע"מ - כלל האוכלוסיה - מגן אגן

Izraēla - ivrits - Ministry of Health

rafa laboratories ltd - ramipril 2.5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Izraēla - ivrits - Ministry of Health

rafa laboratories ltd - ramipril 5 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Izraēla - ivrits - Ministry of Health

rafa laboratories ltd - ramipril 1.25 mg - capsules - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients suffering from impaired renal function.

Izraēla - ivrits - Ministry of Health

teva pharmaceutical indust.ltd - ramipril 2.5 mg - tablets - ramipril - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

Izraēla - ivrits - Ministry of Health

rafa laboratories ltd - pramipexole dihydrochloride monohydrate 0.375 mg - tablets extended release - pramipexole - treatment of signs and symptoms of idiopathic parkinson's disease, as monotherapy or in combination with levodopa.